Higher expression of cell division cycle-associated protein 5 predicts poorer survival outcomes in hepatocellular carcinoma.

Aging
Shengzhong HouBole Tian

Abstract

The upregulation of cell division cycle associated protein 5 (CDCA5) has been observed in various cancer types. However, the prognostic value of CDCA5 and its underlying mechanism contributing to tumorigenesis in hepatocellular carcinoma (HCC) remain poorly understood. We used tissue microarray (TMA) to evaluate the prognosis of 304 HCC samples based on their CDCA5 expression, and analyzed the genomic features correlated with CDCA5 by using dataset from The Cancer Genome Atlas (TCGA). Compared with adjacent normal tissues, increased expression of CDCA5 was found in HCC tissues. Moreover, higher expression of CDCA5 was associated with inferior OS and DFS outcomes in HCC patients. The enrichment plots showed that the gene signatures in cell cycle, DNA replication and p53 pathways were enriched in patients with higher CDCA5 expression. Meanwhile, statistically higher mutations burdens in TP53 could also be observed in CDCA5-high patients. Integrative analysis based on miRNAseq and methylation data demonstrated a potential association between CDCA5 expression and epigenetic changes. In conclusion, our study provided the evidence of CDCA5 as an oncogenic promoter in HCC and the potential function of CDCA5 in affecting tumor microenv...Continue Reading

References

Jun 4, 2002·Nature Reviews. Genetics·Peter A Jones, Stephen B Baylin
Jun 29, 2004·Cancer Letters·Moshe SzyfShafaat A Rabbani
Nov 10, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Robert L CampDavid L Rimm
Aug 17, 2006·Proceedings of the National Academy of Sciences of the United States of America·Peter S GargalovicAldons J Lusis
Aug 29, 2006·Oncogene·W Du, J Pogoriler
Jul 7, 2007·Molecular Cell·Andrew GrimsonDavid P Bartel
Sep 23, 2008·International Journal of Cancer. Journal International Du Cancer·Tae-Min KimYeun-Jun Chung
Oct 29, 2008·Genome Research·Robin C FriedmanDavid P Bartel
Dec 31, 2008·BMC Bioinformatics·Peter Langfelder, Steve Horvath
May 14, 2010·Cold Spring Harbor Perspectives in Biology·David Lane, Arnold Levine
Sep 14, 2010·Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association·Ju Dong YangLewis R Roberts
Jan 1, 2008·CSH Protocols·Andrew H FischerRolf Zeller
Sep 13, 2011·Nature Structural & Molecular Biology·David M GarciaDavid P Bartel
Sep 8, 2012·Advances in Experimental Medicine and Biology·Charles De Smet, Axelle Loriot
Dec 18, 2012·Oncoimmunology·Michael K ShoweLouise C Showe
Feb 4, 2014·Cancer Cell·Raksha MudbharyKirsten C Sadler
Dec 3, 2014·Advanced Drug Delivery Reviews·Ningning YangSidhartha D Ray
Mar 10, 2015·Gastroenterology·Satdarshan Pal Monga
Aug 13, 2015·ELife·Vikram AgarwalDavid P Bartel
Jan 26, 2016·CA: a Cancer Journal for Clinicians·Wanqing ChenJie He
May 6, 2016·Annual Review of Biochemistry·Andreas C Joerger, Alan R Fersht
Jul 13, 2016·Genes & Development·Nicholas J Dyson
Feb 7, 2017·Journal of Genetics and Genomics = Yi Chuan Xue Bao·Yining LiuMin Zhao
Mar 9, 2017·Journal of Experimental & Clinical Cancer Research : CR·Jing SunChuan Su
Jun 18, 2017·Cell·UNKNOWN Cancer Genome Atlas Research Network. Electronic address: wheeler@bcm.edu, UNKNOWN Cancer Genome Atlas Research Network
Sep 16, 2017·Annals of Oncology : Official Journal of the European Society for Medical Oncology·I Huber-RuanoJ Seoane

❮ Previous
Next ❯

Citations


❮ Previous
Next ❯

Methods Mentioned

BETA
RNAseq

Software Mentioned

R package “ GEOquery ”
GSEA
Mutational Significance in Cancer ( MuSiC Genome Suite
R
GDAC Firehose
tile
ONGene
GISTIC
R package edgeR
TargetScan

Related Concepts

Related Feeds

Cancer Epigenetics

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cancer Epigenetics and Senescence (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may be involved in regulating senescence in cancer cells. This feed captures the latest research on cancer epigenetics and senescence.

Cell Signaling & Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. This feed covers the latest research on signaling and epigenetics in cell growth and cancer.

Cancer Epigenetics & Methyl-CpG (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. Here is the latest research on cancer epigenetics and methyl-CpG binding proteins including ZBTB38.

Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Aging Genetics (Keystone)

This feed focuses on aging epidemiology and genetic, epigenetic, and proteomic aspects underlying aging, as well as aging- associated biomarkers. Here the latest research in this domain.

Cancer Epigenetics & Metabolism (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on the relationship between cell metabolism, epigenetics and tumor differentiation.